Zheng Quan Shi Bao Wang·2026-01-04 23:52Group 1 - Company has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as the exclusive sponsor [1] - Company is a research-driven biopharmaceutical firm based in China, focusing on significant unmet medical needs in oncology, autoimmune diseases, and metabolic diseases [1] - As of December 24, 2025, the company has established a comprehensive and differentiated product pipeline, including two commercialized products, two core products in clinical stages, one candidate in clinical stage, and three candidates in preclinical stage [1] Group 2 - The commercialized products include BPI-D0316, a third-generation EGFR tyrosine kinase inhibitor for EGFR mutation-positive non-small cell lung cancer (NSCLC), which has been approved and included in the National Medical Insurance Drug List in China [1] - Another commercialized product, D-1553, is a KRAS G12C inhibitor, the first self-developed product in this target area to enter clinical stages in China, also approved and included in the National Medical Insurance Drug List [1] - The company has signed an agreement with Zhengda Tianqing to grant exclusive rights for the development, registration, production, and commercialization of D-1553 in mainland China [1] Group 3 - The core clinical-stage product D-2570 is undergoing a registrational Phase III clinical trial for plaque psoriasis and ulcerative colitis (UC), with plans to initiate additional trials for psoriatic arthritis (PsA), systemic lupus erythematosus (SLE), and vitiligo [2] - Tairisig is an oral selective estrogen receptor degrader (SERD) currently in a registrational Phase III clinical trial for ER+/HER2- breast cancer [2] - The global and Chinese markets for oncology drugs, targeted oncology drugs, psoriasis drugs, UC drugs, and SERD drugs show significant growth potential, with the Chinese targeted oncology drug market expected to reach $61.6 billion by 2035 [2]